SCHEDULE: Opaleye Management Discloses Karyopharm Stake

Opaleye Management Inc., through its affiliate Opaleye, L.P., has reported beneficial ownership of 619,089 shares of Karyopharm Therapeutics Inc. common stock, representing 2.67% of the outstanding shares, exercisable via warrants.

Summary

• Opaleye Management Inc. and its affiliate Opaleye, L.P., along with James Silverman, have filed a Schedule 13G, indicating their beneficial ownership of Karyopharm Therapeutics Inc. common stock.
• As of March 31, 2026, the total beneficial ownership is 619,089 shares, which are issuable upon the exercise of warrants.
• This holding represents 2.67% of Karyopharm Therapeutics Inc.'s outstanding common stock.
• The filing is made under Rule 13d-1(b) and designates Opaleye Management Inc. as an investment adviser.
• The reporting persons have shared power to vote and dispose of these shares.
• The filing explicitly states that this should not be construed as an admission of beneficial ownership for purposes of Section 13 of the Securities Exchange Act, beyond what is reported.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily a disclosure of an existing investment position rather than a significant strategic development or financial performance update.

Positives

• Opaleye Management Inc. and its affiliate have disclosed a significant stake in Karyopharm Therapeutics Inc., indicating investment interest.
• The stake is exercisable via warrants, suggesting a potential for increased ownership upon exercise.

Negatives

• The filing explicitly denies beneficial ownership beyond what is reported, which could imply a limited or strategic investment rather than a controlling interest.
• The reporting persons have no sole voting or dispositive power, with all shares held under shared power.

Risks

• The filing does not detail specific risks associated with Karyopharm Therapeutics Inc. or the investment itself.
• Potential future regulatory changes or market conditions could impact the value of the warrants or the underlying common stock.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from Karyopharm Therapeutics Inc. It only reports the current ownership stake by Opaleye Management and its affiliates.

Management Comments

• The filing of this statement should not be construed as an admission that any of the foregoing persons is, for the purposes of Section 13 of the Securities Exchange Act, the beneficial owner of the warrants reported herein.
• The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and investment advisers accumulating significant stakes in public companies, often through warrants or options, indicating active portfolio management within the biotechnology sector.

Stakeholder Impact

• Shareholders of Karyopharm Therapeutics Inc.: The disclosure of a significant stake by an investment adviser may signal investor confidence or potential future strategic actions, which could influence share price.
• Management of Karyopharm Therapeutics Inc.: The reporting persons' statement regarding not influencing control suggests a passive investment approach, which may be viewed favorably by current management.
• Potential Investors: This filing provides transparency on ownership, allowing other investors to assess the shareholder base.

Next Steps

• Opaleye Management Inc. and its affiliates will continue to hold and potentially exercise their warrants.
• Further filings may be required if their ownership stake changes significantly.

Key Dates

Keywords

Karyopharm Therapeutics, Schedule 13G, Opaleye Management, Opaleye L.P., James Silverman, Beneficial Ownership, Warrants, SEC Filing, Investment Adviser